

Advanced Endometrial Cancer - Pipeline Insight, 2021

<https://marketpublishers.com/r/AEEC1B427168EN.html>

Date: September 2021

Pages: 60

Price: US\$ 2,000.00 (Single User License)

ID: AEEC1B427168EN

Abstracts

This report can be delivered to the clients within 3-5 business days

DelveInsight's, "Advanced Endometrial Cancer - Pipeline Insight, 2021," report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Advanced Endometrial Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Advanced Endometrial Cancer Understanding

Advanced Endometrial Cancer: Overview

Metastatic or advanced uterine (endometrial) cancer is a type of cancer that originated in the lining of the uterus (endometrium) and has spread to distant areas of the body. In general, uterine cancer can metastasize to the rectum or bladder. Other areas where it may spread include the vagina, ovaries and fallopian tubes. This form of cancer is typically slow growing and often detected before it has spread to more distant areas of the body. Different types of treatment are available for patients with endometrial cancer. Some treatments are standard (the currently used treatment), and some are being tested in clinical trials. Surgery (removing the cancer in an operation) is the most common treatment for endometrial cancer. Radiation therapy is a cancer treatment that uses high-energy x-rays or other types of radiation to kill cancer cells or keep them from

growing.

'Advanced Endometrial Cancer - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Advanced Endometrial Cancer pipeline landscape is provided which includes the disease overview and Advanced Endometrial Cancer treatment guidelines. The assessment part of the report embraces, in depth Advanced Endometrial Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Advanced Endometrial Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Advanced Endometrial Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Advanced Endometrial Cancer.

Advanced Endometrial Cancer Emerging Drugs Chapters

This segment of the Advanced Endometrial Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Advanced Endometrial Cancer Emerging Drugs

Retifanlimab: Incyte Corporation

Retifanlimab (formerly INCMGA0012), an investigational intravenous PD-1 inhibitor, is currently under evaluation in registration-directed trials as a monotherapy for patients with microsatellite instability-high endometrial cancer, Merkel cell carcinoma and squamous cell carcinoma of the anal canal (SCAC); and in combination with platinum-

based chemotherapy for patients with non-small cell lung cancer and SCAC.

Trastuzumab duocarmazine (SYD985): Byondis

The most advanced compound in the company's pipeline is trastuzumab duocarmazine (US non-proprietary name [vic-]trastuzumab duocarmazine). This investigational anti-HER2 ADC, targets a broad range of HER2-expressing cancers such as (metastatic) breast, gastric, bladder (urothelial) and uterine (endometrial) cancer. Trastuzumab duocarmazine could be used in patients where other (anti-HER2) treatments have failed, reflecting our philosophy of developing new, innovative medicines for relentless cancers. Trastuzumab duocarmazine is Byondis' frontrunner ADC. The antibody, trastuzumab, can bind to a specific protein, HER2 (Human Epidermal growth factor Receptor 2) on the cell surface of tumor cells in many different tumor types. The linker-drug in trastuzumab duocarmazine is vc-seco-DUBA.

Further product details are provided in the report.

Advanced Endometrial Cancer: Therapeutic Assessment

This segment of the report provides insights about the different Advanced Endometrial Cancer drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Advanced Endometrial Cancer

There are approx. 25+ key companies which are developing the therapies for Advanced Endometrial Cancer. The companies which have their Advanced Endometrial Cancer drug candidates in the most advanced stage, i.e. phase II include, Incyte Corporation.

Phases

DelveInsight's report covers around 25+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Advanced Endometrial Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

intravenous

Subcutaneous

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Advanced Endometrial Cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Advanced Endometrial Cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Advanced Endometrial Cancer drugs.

Advanced Endometrial Cancer Report Insights

Advanced Endometrial Cancer Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Advanced Endometrial Cancer Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Advanced Endometrial Cancer drugs?

How many Advanced Endometrial Cancer drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Advanced Endometrial Cancer?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Advanced Endometrial Cancer therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Advanced Endometrial Cancer and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Incyte Corporation

Byondis B.V.

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Ability Pharmaceuticals SL

Zymeworks Inc.

AstraZeneca

Eli Lilly and Company

Pfizer

Karyopharm Therapeutics

Genentech

Eli Lilly and Company

Genentech, Inc.

NETRIS Pharma

Five Prime Therapeutics, Inc.

Millennium Pharmaceuticals, Inc.

Novartis Oncology

Takeda

Mundipharma-EDO GmbH

Zai Lab (Shanghai) Co., Ltd.

Haihe Biopharma Co., Ltd.

Xencor

Compugen Ltd

Checkpoint Therapeutics, Inc.

Celon Pharma SA

Dragonfly Therapeutics

Key Products

Retifanlimab

Bevacizumab

Abemaciclib

CYH33

Niraparib

EDO-S101

Trastuzumab duocarmazine

Serabelisib

Lacnotuzumab

TQB2450

ABTL0812

DF6002

Sapanisertib

COM701

ZW25

NP 137

CK-301

FPA150

Cediranib

LY3484356

PF-06939999

Selinexor

Atezolizumab

XmAb®23104

CPL304110

Contents

Introduction

Executive Summary

Advanced Endometrial Cancer: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Advanced Endometrial Cancer – DelveInsight's Analytical Perspective

Late Stage Products (Phase III)

Comparative Analysis

Selinexor: Karyopharm Therapeutics

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.

Mid Stage Products (Phase II)

Comparative Analysis

Retifanlimab: Incyte Corporation

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.

Early Stage Products (Phase I)

Comparative Analysis

Asevalimab: Five Prime Therapeutics

Product Description

Research and Development
Product Development Activities
Drug profiles in the detailed report.
Inactive Products
Comparative Analysis
Advanced Endometrial Cancer Key Companies
Advanced Endometrial Cancer Key Products
Advanced Endometrial Cancer- Unmet Needs
Advanced Endometrial Cancer- Market Drivers and Barriers
Advanced Endometrial Cancer- Future Perspectives and Conclusion
Advanced Endometrial Cancer Analyst Views
Advanced Endometrial Cancer Key Companies
Appendix

List Of Tables

LIST OF TABLES

Introduction

Executive Summary

Advanced Endometrial Cancer: Overview

- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management

Pipeline Therapeutics

- Comparative Analysis

Therapeutic Assessment

- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type

Advanced Endometrial Cancer – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

- Advanced Endometrial Cancer companies' collaborations, Licensing, Acquisition -Deal Value Trends

Advanced Endometrial Cancer Collaboration Deals

- Company-Company Collaborations (Licensing / Partnering) Analysis
- Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

- Comparative Analysis

Selinexor: Karyopharm Therapeutics

- Product Description
- Research and Development
- Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

- Comparative Analysis

Retifanlimab: Incyte Corporation

- Product Description

- Research and Development
 - Product Development Activities
- Drug profiles in the detailed report.....

Early Stage Products (Phase I)

- Comparative Analysis
- Alsevalimab: Five Prime Therapeutics
- Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report.....

Inactive Products

- Comparative Analysis
- Advanced Endometrial Cancer Key Companies
- Advanced Endometrial Cancer Key Products
- Advanced Endometrial Cancer- Unmet Needs
- Advanced Endometrial Cancer- Market Drivers and Barriers
- Advanced Endometrial Cancer- Future Perspectives and Conclusion
- Advanced Endometrial Cancer Analyst Views
- Advanced Endometrial Cancer Key Companies
- Appendix

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Advanced Endometrial Cancer
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Advanced Endometrial Cancer - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/AEEC1B427168EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/AEEC1B427168EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970